IN THE CLAIMS:

Please add new claims 68-77.

This listing of claims will replace all prior versions, and listings of the claims in the application.

Listing of the claims

1-22. (Canceled)

23. (Previously presented) A pharmaceutical composition that can be used to treat metastatic colorectal cancer comprising;

a) a ST receptor binding ligand selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor;

b) a non-peptide radiostable cytotoxic or cytostatic agent; and,

c) a pharmaceutical carrier or diluent;

wherein said peptides that bind to ST receptor, activates guanylyl cyclase C and said pharmaceutical composition is an injectable pharmaceutical composition.

24. (Canceled)

25. (Previously presented) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor,

wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

26. (**Previously presented**) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

27. (**Previously presented**) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

28-29. (Canceled)

30. (**Previously presented**) The pharmaceutical composition of claim 23 wherein said non-peptide radiostable cytotoxic or cytostatic agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

31. (**Previously presented**) The pharmaceutical composition of claim 23 wherein said cytotoxic or cytostatic agent is 5-fluorouracil.

32. (**Previously presented**) The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST

receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor, and the non-peptide radiostable cytotoxic or cytostatic agent is selected from the group consisting of; methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

33. (**Previously presented**) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

34. (**Previously presented**) The pharmaceutical composition of claim 32 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

35. **(Canceled)**

36. (**Previously presented**) The pharmaceutical composition of claim 32 wherein said non-peptide radiostable cytotoxic or cytostatic agent is 5-fluorouracil.

37-38. (Canceled)

39. (**Previously presented**) The pharmaceutical composition of claim 33 wherein said non-peptide radiostable cytotoxic or cytostatic agent is 5-fluorouracil.

40. (**Previously presented**) The pharmaceutical composition of claim 39 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

41. **(Canceled)**

42. (**Previously presented**) A pharmaceutical composition that can be used to treat metastatic colorectal cancer comprising:

a) a ST receptor binding ligand selected from group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor;

b) a radiostable active agent, wherein the radiostable active agent is a cytotoxic or cytostatic agent; and,

c) a pharmaceutical carrier or diluent;

wherein said peptides that bind to ST receptor activate guanylyl cyclase C and said pharmaceutical composition is an injectable pharmaceutical composition that is a liposome comprising a vesicle matrix wherein the ST receptor binding ligand is in the vesicle matrix and the active agent is inside the liposome.

43. (**Previously presented**) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides that bind to ST

receptor, wherein said fragments and derivatives bind to ST receptor, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fiuorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

44. (**Previously presented**) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence of SEQ ID NO:2 and the active agent is 5-fluorouracil.

45. (**Previously presented**) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

46. (**Previously presented**) The pharmaceutical composition of claim 42 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin. vindesine, milomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens

phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

47. (**Previously presented**) The pharmaceutical composition of claim 42 wherein the active agent is a non-peptide.

48. (**Previously presented**) A pharmaceutical composition that can be used to treat metastatic colorectal cancer comprising:

a) a ST receptor binding ligand selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor;

b) an active agent selected from the group consisting of: cytotoxic or cytostatic agents;

c) a pharmaceutical carrier or diluent; wherein said composition is unconjugated; wherein said pharmaceutical composition is an injectable pharmaceutical composition.

49. **(Canceled)**

50. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and

fragments and derivatives thereof that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

51. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

52. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

53. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said active agent is non-peptide.

54. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said active agent is radiostable.

55. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said active agent is a cytotoxic or a cytostatic agent.

56. (**Previously presented**) The pharmaceutical composition of claim 48 wherein the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A

chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

57-61. (Canceled)

62. **(Previously presented)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2. SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

63. **(Previously presented)** The pharmaceutical composition of claim 23 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor, and the non-peptide radiostable cytotoxic or cytostatic agent is selected from the group consisting of; methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, and 1,4-benzoquinone derivatives.

64. **(Previously presented)** The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group

consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor, and the active agent is selected from the group consisting of: methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-fluorouracil, melphalan, chlorambucil, cis-platin, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, alkaline phosphatase, nitroimidazole, metronidazole and misonidazole.

65. (**Previously presented**) The pharmaceutical composition of claim 42 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

66. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST-10-receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-54 and

fragments and derivatives thereof that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

67. (**Previously presented**) The pharmaceutical composition of claim 48 wherein said ST receptor binding ligand is a peptide that binds to ST receptor and activates guanylyl cyclase C.

68. (**New**) The pharmaceutical composition of claim 23 comprising a non-peptide radiostable cytotoxic agent.

69. (**New**) The pharmaceutical composition of claim 68 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives of such peptides that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

70. (**New**) The pharmaceutical composition of claim 68 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

71. (**New**) The pharmaceutical composition of claim 68 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

72. (**New**) The pharmaceutical composition of claim 48 comprising a cytotoxic agent.

73. (**New**) The pharmaceutical composition of claim 72 wherein said ST receptor binding ligand is selected from the group consisting of: antibodies that bind to ST receptor, antibody fragments that bind to ST receptor and peptides that bind to ST receptor, wherein said peptides that bind to ST receptor are selected from the group consisting of peptides having the amino acid sequences of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NOS:5-56 and fragments and derivatives thereof that bind to ST receptor, wherein said fragments and derivatives bind to ST receptor.

74. (**New**) The pharmaceutical composition of claim 72 wherein said ST receptor binding ligand is a peptide having an amino acid sequence selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:6 and SEQ ID NO:54.

75. (**New**) The pharmaceutical composition of claim 72 wherein said ST receptor binding ligand is a peptide having the amino acid sequence of SEQ ID NO:2.

76. (**New**) The pharmaceutical composition of claim 72 wherein said active agent is non-peptide.

77. (**New**) The pharmaceutical composition of claim 72 wherein said active agent is radiostable.